Measurable neural biomarkers of mood and affect
Identifying signals in brain activity that track a person's mood, motivation and emotional state accurately enough to serve as a control variable.
State of the art
Closed-loop neuromodulation driven by an intracranial amygdala biomarker produced rapid sustained improvement in one patient with treatment-resistant depression (Nature Medicine 2021); FDA approved adaptive DBS with sensing for Parkinson's in 2025.
- Biomarkers do not generalize across people; each requires weeks of intracranial mapping
- Ground truth is subjective self-report, so the mapping cannot be validated objectively
- Emotion is not a small set of dials; no evidence that discrete states like "ersatz dread" are separately addressable
Who’s working on it
- Katherine ScangosResearcherUCSF Dolby Family Center for Mood Disorders
Led the 2021 n-of-1 study that found a personalized amygdala gamma biomarker and used it to trigger closed-loop stimulation for depression
- Helen MaybergResearcherIcahn School of Medicine at Mount Sinai
Her group used a sensing DBS device to identify a recording-based biomarker tracking recovery from treatment-resistant depression (NIH-reported, 2023)
- Sameer ShethResearcherBaylor College of Medicine
Runs intracranial-recording-guided DBS trials for depression at Baylor and co-founded Motif Neurotech (PI of its 2026 RESONATE study)
- UCSF Closed-Loop DBS Program ↗Academic lab
Multi-subject program mapping personalized iEEG mood biomarkers before chronic closed-loop DBS, with a sham-controlled phase
- Inner Cosmos ↗Startup
Completed an FDA early feasibility study of a skull-embedded depression stimulator in 2025, reporting remission in its third patient
- ARPA-H EVIDENTProgram
Behavioral-health program funding teams to collect objective data on which patients respond to rapid-acting mental-health interventions; Motif Neurotech selected in 2026
What to invest in
| Kind | Investment | Scale |
|---|---|---|
| research | Multi-site intracranial mood-mapping cohorts large enough to test cross-subject biomarker generalization | $$ $10M – $100M |
Depends on
A root node: no prerequisites modeled.